Physician profile
Vinay Reddy
NPI 1275535536
$46,185.66
in general payments reported to CMS, 2019-2025
43 companies · $590 in 2025
The $590 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $4,815 · 2021: $3,498 · 2022: $9,518 · 2023: $4,395 · 2024: $4,816 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,800.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $14,540.16 | 2019-2023 | Krystexxa |
| Genzyme Corporation | $5,929.17 | 2019-2024 | |
| Abbvie INC. | $4,443.61 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $3,755.52 | 2021-2024 | Lupkynis |
| Amgen INC. | $2,393.26 | 2019-2024 | Krystexxa, Enbrel, Amjevita |
| Janssen Biotech, INC. | $1,811.82 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Mallinckrodt Hospital Products INC. | $1,694.55 | 2020-2024 | Acthar |
| Ucb, INC. | $1,528.51 | 2019-2024 | Cimzia, Bimzelx |
| Pfizer INC. | $1,377.56 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $1,223.37 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,101.86 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $1,038.53 | 2019-2024 | Orencia |
| Ani Pharmaceuticals, INC. | $1,009.53 | 2022-2024 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $993.75 | 2019 | |
| Lilly USA, LLC | $655.89 | 2019-2024 | Taltz |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinay Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.